Latest Non-steroidal anti-inflammatory drugs Stories
First PCORnet Demonstration Study Could Help Guide Treatment Options for Millions WASHINGTON, May 4, 2015 /PRNewswire-USNewswire/ -- The
NEWARK, Calif., April 30, 2015 /PRNewswire/ -- Depomed, Inc.
OTTAWA, April 23, 2015 /CNW/ - Health Canada is working with the Canadian manufacturers of prescription oral ibuprofen products to update the safety information regarding the risk of serious cardiovascular
Planned ASCRS Symposium events and sessions will highlight Imprimis' Dropless Therapy and Combination Drop Therapy SAN DIEGO, April 15, 2015 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc.
OTTAWA, April 10, 2015 /CNW/ - The issue: Ranbaxy Pharmaceuticals Canada Inc., in consultation with Health Canada, is recalling one batch of RAN-Gabapentin, a medication used
DeepResearchReports.com adds “2015 Market Research Report on Global Salicylic Acid (SA) Industry” and “2015 Deep Research Report on Global Tranexamic Acid Industry” market research reports
- Initial Hepatoren® Phase II study results NASHVILLE, Tenn., March 3, 2015 /PRNewswire/ -- Cumberland Pharmaceuticals Inc.
NEWARK, Calif., March 3, 2015 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will be presenting at the 27(th) Annual Roth Conference in Laguna Niguel, California.
NEWARK, Calif., Feb. 12, 2015 /PRNewswire/ -- Depomed, Inc.
CAMBIA® (Diclofenac Potassium for Oral Solution) is elevated to Level A, based on rigorous clinical data demonstrating its effectiveness for acute migraine attacks, consistent with other therapies
- an ornament or knob in the shape of a flower
More Images (1 images) »